Seroprevalence of SARS-CoV-2 IgG Antibodies among PostInfection COVID-19 Patients and Post Vaccination at a Tertiary Care Hospital
The SARS-CoV-2 pandemic has generated a global health crisis, which needs more comprehensive analysis into immunological reactions to improve treatment and vaccine options.
The aim of this study was to evaluate SARS COV2 spike protein antibodies against COV19 in post infection and post vaccinated individuals.
256 patients were included in this cross sectional study conducted at Rehman Medical Institute (RMI), Peshawar. We described the immunogenicity 35 days after vaccination and 90 days after infection in 70 patients and established its correlation with age and gender, specimens were collected and investigated for SARS-CoV-2 spike protein antibodies by consuming Electrochemiluminescence immunoassay (ECLIA) (Abbot Advice Dx SARS-CoV-2 IgG II assay (USA).
97% of patients revealed robust positive findings to SARS COV2 spike proteins antibodies i.e. >50 IU/mL. Our study shows that post infected and post vaccinated individuals can mount robust immune reactions against SARS-CoV-2.
Majority of the patients had significant higher antibody titers against SARS COV2 after infection and vaccination. Males and younger individuals developed a significant humoral immunity compared to females. Those vaccinated had antibody titers one scale higher than infected patients. Constant monitoring of antibodies titers in infected or vaccinated population is estimated to attain humoral immunity grade against SARS-CoV-2 infection.